Search
Curriculum-Exam Committee
Current committee members
Jose Tomás Navarro Ferrando, Spain (Chair)
Marielle Wondergem, The Netherlands (Vice-Chair and Progress test lead)
Alicia Rovó, Switzerland (Representative, Swiss Society)
Regular members
Gunnar Birgegård, Sweden
Roza Chaireti, Sweden
Carlos Fernández de Larrea, Spain
Mahesh Prahladan, United Kingdom
Ulla Wartiovaara-Kautto, Finland
AimTo promote harmonization in hematology training…
EHA2025 Congress
Join us for the 30th EHA Congress, taking place in Milan from June 12–15, 2025, as we revolutionize the way we learn and connect in hematology.
Read moreEHA policy on double awarding
EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.
Read moreMeeting Report: European School of Haematology International Conference of Haematological Disorders in the Elderly
The meeting started by reviewing demographic aspects, physiological changes encountered in the elderly, as well as the definition of older and elderly people, frailty and comorbidity.
Read moreSPC Advisory Board, EHA2025 Congress
Current committee members
Lorena Arranz, Norway
Peter Borchmann, Germany
Veronika Buxhofer-Ausch, Austria
Ana Cvejic, Denmark
Matteo Della Porta, Italy
Michael Doubek, Czechia
Andreas Glenthøj, Denmark
Maria Gomes da Silva, Portugal
Julia Hauer, Germany
Daniel Hodson, United Kingdom
Cristina João, Portugal
Sören Lehmann, Sweden
Tamás Masszi, Hungary
Karinna Meijer, The Netherlands
Jamie O'Sullivan, Ireland
Cristina Papayannidis, Italy
France…
Special airfare discount
A 10% discount on Air France or KLM airfares for EHA2025 attendees. If you'll be flying to EHA2025, you can benefit from a special discount courtesy of Air France-KLM Global Meetings & Events.
Read moreFDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »